Kevin Pritchard
CSO Nanoptima
Formerly Head of Protein Science at AstraZeneca, previously Head of Protein Science at Cambridge Antibody Technology. 20 Years’ pharma and biotech experience in protein and small molecule therapeutics, peptide and protein design.
Seminars
Thursday 29th January 2026
5 Advances in Biodegradable Platforms: Balancing Controlled Release, Safety, & Patient Convenience
12:45 pm
- Exploration of degradable materials that clear completely from the eye, emphasizing biocompatibility, control over burst release, and the ability to implant repeatedly as needed for chronic conditions
- Learn about shear-thinning peptidic gels for fine-needle injectable vitreal delivery; composed entirely of short chains of natural amino acids having modular functional properties; delivers unmodified biologics, including proven antiangiogenic proteins
- Discover the formulation using industry-standard media at neutral pH and dissolution of a matrix that does not require hydrolysis of any covalent bonds
- Uncover drug retention and release rates tuneable by rational modification of gel structure, ionic and hydrophobic properties, and designed drug-peptide interactions; high capacity for large protein drugs
